ATE326222T1 - Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch - Google Patents

Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Info

Publication number
ATE326222T1
ATE326222T1 AT01920377T AT01920377T ATE326222T1 AT E326222 T1 ATE326222 T1 AT E326222T1 AT 01920377 T AT01920377 T AT 01920377T AT 01920377 T AT01920377 T AT 01920377T AT E326222 T1 ATE326222 T1 AT E326222T1
Authority
AT
Austria
Prior art keywords
naltrexone
naloxone
treatment
analogs
pain
Prior art date
Application number
AT01920377T
Other languages
English (en)
Inventor
Wolfgang Sadee
Danxin Wang
Original Assignee
Wolfgang Sadee
Danxin Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22697044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326222(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wolfgang Sadee, Danxin Wang filed Critical Wolfgang Sadee
Application granted granted Critical
Publication of ATE326222T1 publication Critical patent/ATE326222T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01920377T 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch ATE326222T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18937200P 2000-03-15 2000-03-15

Publications (1)

Publication Number Publication Date
ATE326222T1 true ATE326222T1 (de) 2006-06-15

Family

ID=22697044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920377T ATE326222T1 (de) 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Country Status (7)

Country Link
US (2) US20010049375A1 (de)
EP (1) EP1263438B1 (de)
AT (1) ATE326222T1 (de)
AU (1) AU4743601A (de)
CA (1) CA2403252A1 (de)
DE (1) DE60119696T2 (de)
WO (1) WO2001068080A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
EP2266564B1 (de) 1997-12-22 2013-03-13 Euro-Celtique S.A. Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem opioid Agonisten und einem opioid Antagonisten
EP2517710B1 (de) 2000-02-08 2015-03-25 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
CA2454328C (en) 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
SI2939696T1 (sl) * 2001-10-18 2016-06-30 Nektar Therapeutics Polimerni konjugati opioidnih antagonistov
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
LT2425824T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP4545584B2 (ja) 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EA018427B1 (ru) * 2003-12-16 2013-07-30 Нектар Терапьютикс Химически модифицированный налоксон
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20070197573A1 (en) * 2005-10-04 2007-08-23 Wolfgang Sadee Compositions and methods in the treatment of bone metabolic disorders
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
CN1813740B (zh) * 2005-11-22 2010-05-05 岳振江 一种含有盐酸纳洛酮的舌下膜剂及其制备方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2719378B1 (de) 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmazeutische Zusammensetzungen
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
CA2668885C (en) * 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20100129818A1 (en) * 2007-04-30 2010-05-27 The Ohio State University Research Foundation Polymorphisms in Genes Affecting CYP2C9-Related Disorders and Uses Thereof
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
HUE042105T2 (hu) 2009-03-10 2019-06-28 Euro Celtique Sa Oxikodont és naloxont tartalmazó azonnali hatóanyagleadású orális gyógyászati készítmények
EP3659604A1 (de) * 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
WO2011139525A1 (en) * 2010-05-05 2011-11-10 Philadelphia Health & Education Corporation Stereoisomer of naloxone and potential therapeutic action of opioid drugs to reverse clinical tolerance to these agents
EP2630150B1 (de) * 2010-10-19 2017-04-12 Memorial Sloan-Kettering Cancer Center 6-amido-derivat aus 4,5-a-epoxymorphinanen zur schmerzbehandlung
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans
EP3024461B1 (de) 2013-07-23 2020-05-13 Euro-Celtique S.A. Kombination aus oxycodon und naloxon für die verwendung bei der behandlung von schmerzen bei patienten mit schmerzen und einer krankheit, die zur intestinaldysbiose und/oder erhöhung der gefahr bakterieller translokation führt
DK3148517T3 (da) 2014-05-30 2021-07-26 The Resaerch Foundation For The State Univ Of New York Sammensætninger og fremgangsmåder til fremme af knogledannelse
EP4212532A3 (de) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynin-analoga und verwendungen davon
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10925870B2 (en) 2016-01-08 2021-02-23 Ohio State Innovation Foundation Treatments and prevention of opioid neonatal abstinence syndrome
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
KR20200072445A (ko) 2017-03-28 2020-06-22 엘디엔 파마 리미티드 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2020142644A1 (en) 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency
JP7502320B2 (ja) * 2019-03-06 2024-06-18 エルディーエヌ ファーマ リミテッド 効力を判定するための方法
WO2021011529A1 (en) 2019-07-15 2021-01-21 Rovaxa Opioid growth factor receptor (ogfr) antagonists, in particular naloxone and/or naltrexone for treating cancer
JP7689568B2 (ja) 2020-07-17 2025-06-06 ゼタゲン セラピューティクス，インコーポレイティド 鉄賦形剤を用いた組成物及びがん治療を含むその用途
US20240325379A1 (en) * 2021-07-06 2024-10-03 Aether Therapeutics Inc. Low-dose naltrexol and uses thereof
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
US12403118B1 (en) 2025-03-05 2025-09-02 Zetagen Therapeutics, Inc. Cancer treatments using modified fatty acids and the carriers to administer them

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254088A (en) 1961-03-14 1966-05-31 Lewenstein Morphine derivative
NL137652C (de) 1962-07-11
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (de) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4816586A (en) 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5051426A (en) 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
CH683005A5 (it) * 1991-10-30 1993-12-31 Aldo Massarotti Procedimento per la preparazione, mediante ossidazione di N-ossidi per le terapie dei tossicomani da oppiati.
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6007986A (en) 1993-06-23 1999-12-28 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic activity screening
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
WO1996014071A1 (es) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combinacion de farmacos como medicamento destinado a supresion de dependencia de individuos a opiaceos
AU5374996A (en) 1995-03-31 1996-10-16 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
CA2220768A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5760044A (en) * 1996-05-16 1998-06-02 Archer; Sydney Method for treating cocaine and amphetamine dependency
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
EP1011671A1 (de) * 1997-05-20 2000-06-28 Yale University Entwöhnungstherapie mit opiat- und serotoninantagonisten
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion

Also Published As

Publication number Publication date
DE60119696T2 (de) 2007-01-25
US20030069262A1 (en) 2003-04-10
DE60119696D1 (de) 2006-06-22
WO2001068080A2 (en) 2001-09-20
EP1263438A2 (de) 2002-12-11
EP1263438B1 (de) 2006-05-17
AU4743601A (en) 2001-09-24
CA2403252A1 (en) 2001-09-20
US6713488B2 (en) 2004-03-30
WO2001068080A3 (en) 2002-07-04
US20010049375A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DE60119696D1 (de) Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
WO2004017941A3 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
CA2302754A1 (en) Noribogaine in the treatment of pain and drug addiction
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
NO20001175D0 (no) Smertestillende blandinger omfattende anti-epileptiske forbindelser og fremgangsmÕter for anvendelse derav
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
KR970009799A (ko) 물질 남용 금단의 치료 방법
WO2001091736A3 (en) Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
SE9902597D0 (sv) New use
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
Komoda et al. Enhancement of lidocaine-induced epidural anesthesia by deoxyaconitine in the rabbit
WO2007059445A3 (en) Synergistic combinations of norketamine and opioid analgesics
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
US20040198723A1 (en) Method of treatment
MD1610F1 (en) Method of the recidivating chronic aphthous stomatitis treatment
Hanks Current Availability and Use of Morphine in Developed Countries and Relevance of Alternative Opioids to Morphine in Clinical Practice

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties